In order to bolster its gastrointestinal and hepatology portfolio, Alfasigma has agreed to acquire Intercept for US$794 M. Through the deal, Alfasigma will gain access to Intercept’s lead product, Ocaliva (obeticholic acid), and its pipeline assets which will help the former to expand its presence in the US market. Interestingly, this deal comes shortly after Intercept discontinued all nonalcoholic steatohepatitis (NASH)-related investments after the US FDA rejected Ocaliva’s drug approval in this indication.